Yourgene Health PLC Directors' dealing & warrant extension (4353Y)
May 09 2019 - 1:00AM
UK Regulatory
TIDMYGEN
RNS Number : 4353Y
Yourgene Health PLC
09 May 2019
Yourgene Health plc
("Yourgene," the "Company")
Directors' dealing and warrant extension
Manchester, UK - 9 May 2019: Yourgene (AIM: YGEN), a leading
international molecular diagnostics group, announces that it was
notified yesterday by Barry Hextall and Hayden Jeffreys, both
directors of the Company, that they respectively purchased 89,551
and 222,348 ordinary shares of 0.10p each in the Company yesterday
at an average price of 11.2 pence per ordinary share. The table
below details each directors' shareholdings:
Director Shareholding Number of ordinary Shareholding Ordinary
prior to purchase shares purchased following shares held
of shares purchase of as percentage
shares of issued
voting share
capital
Barry Hextall 432,518 89,551 522,069 0.09%
------------------- ------------------- ------------- ---------------
Hayden Jeffreys 0 222,348 222,348 0.04%
------------------- ------------------- ------------- ---------------
Extension of warrant
Furthermore, the Company announces that it has agreed to extend
the exercise period by a year of a warrant granted over 1,411,227
ordinary shares that was scheduled to expire on 13 June 2019.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For more information, please contact:
Yourgene Health plc Tel: +44 (0)16 1667 1053
Lyn Rees, Chief Executive Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
investors@yourgene-health.com
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20 7213 0880
Liam Murray / James Caithie
Stifel Nicolaus Europe Limited (Broker) Tel: +44 (0)20 7710 7600
Nicholas Moore / Matthew Balwat / Ben
Maddison
Vigo Communications Tel: +44 (0)20 7390 0234
Ben Simons / Fiona Henson / Antonia
Pollock
yourgene@vigocomms.com
About Yourgene Health
Yourgene Health is an international molecular diagnostics group
which develops and commercialises genetic products and services.
The group works in partnership with global leaders in DNA
technology to advance diagnostic science.
Our product development, research service and commercial
capabilities extend across the lifecycle of genetic test
development including regulatory submissions.
Yourgene Health's first commercialised products are NIPT for
Down's Syndrome and other genetic disorders, targeting a share of
an emerging billion-dollar global market.
Prenatal screening is an established clinical practice, but
accuracy challenges with traditional methods are driving the need
for NIPT and other DNA-based reproductive health testing solutions.
Our commercial footprint is already established in the UK, Europe,
the Middle East, Africa and Asia.
Through our technical expertise and partnerships, Yourgene
Health is aiming to extend its genetic testing offering into
complementary areas of reproductive health and oncology.
Yourgene Health is headquartered in Manchester, UK with offices
in Taipei and Singapore, and is listed on the London Stock
Exchange's AIM market under the ticker "YGEN". For more information
visit www.yourgene-health.com and follow us on twitter
@Yourgene_Health.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----- --------------------------------------------------------------------------------
a. Name (i) Barry Hextall
(ii) Hayden Jeffreys
-------------------------------------------------
2 Reason for notification
----------------------------- -------------------------------------------------
a. Position/Status (i) Chief Financial Officer
(ii) Chief Operating Officer
----------------------------- -------------------------------------------------
b. Initial notification/ Initial notification
Amendment
-------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Yourgene Health plc
-----------------------------
b. LEI 213800UUIT8BZE7QEH33
----------------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----- --------------------------------------------------------------------------------
a. Description of Ordinary shares of 0.10p each
the financial
instrument, type ISIN: GB00BN31ZD89
of instrument
Identification
Code
----------------------------- -------------------------------------------------
b. Nature of the Purchase of ordinary shares
transaction
----------------------------- -------------------------------------------------
c. Price(s) and volume(s) Price(s) Volume(s)
----------------------------- ------------------
(i) 11.5p (i) 89,551
(ii) 11.5p (ii) 222,348
------------------ --------------------
Aggregated information
- Aggregated Volume 311,899
d. - Price 11.5p
----------------------------- -------------------------------------------------
e. Date of the transaction 8 May 2019
----------------------------- -------------------------------------------------
f. Place of the transaction London Stock Exchange
----------------------------- -------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHKMGGKVRGGLZM
(END) Dow Jones Newswires
May 09, 2019 02:00 ET (06:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024